.Nature Medicine, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Perspective calls for introduction of patients along with MASLD and also size of liver outcomes in cardio-- kidney-- metabolic trials, when information advise mechanistically plausible advantages and clinical safety-- as well as lays out factors to consider for trial layout as well as regulative commendation.